Monday, November 25, 2024

HHS NIH and CDC Solicitation: Small Business Innovation Research (SBIR) Contract Proposals

Updated September 23, 2021

Notice ID: PHS-2022-1

“The purpose of this amendment is to:

  • Provide slides, recording, and transcript of the pre-proposal conference;
  • Regarding Solicitation Section 2.5 I-CorpsTM at NIH: To clarify that CDC/NIOSH (National Institute of Occupational Safety and Health) does participate in the iCorps program, but not as a part of this solicitation;
  • Amend Solicitation Section 12, NCI Topic 433 Developing Unbiased Medical Technologies to Reduce Disparities in Cancer Outcomes, to remove paragraph one under Project Goals, which was included in error; …”

Read more here.


Posted August 6, 2021

Notice ID: PHS-2022-1

“The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) are soliciting proposals from small business concerns that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward NIH or CDC mission needs and Small Business Innovation Research (SBIR) program objectives.”

“THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), THE NATIONAL INSTITUTES OF HEALTH (NIH), AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PROGRAM SOLICITATION PHS-2022-1 is anticipated to be made available on or around July 28, 2021, through both SAM.gov and the NIH Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) funding web page at https://sbir.nih.gov/funding. This solicitation is anticipated to have a closing date of October 28, 2021 for receipt of proposals.”

“The purposes of the SBIR program are to: (a) stimulate technological innovation; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and (d) increase private sector commercialization of innovations derived from Federal R/R&D, thereby increasing competition, productivity and economic growth…”

Read more here.

[related-post]

LEAVE A REPLY

Please enter your comment!
Please enter your name here

FedHealthIT Xtra – Find Out More!

Recent News

Don’t Miss A Thing

Jackie Gilbert
Jackie Gilbert
Jackie Gilbert is a Content Analyst for FedHealthIT and Author of 'Anything but COVID-19' on the Daily Take Newsletter for G2Xchange Health and FedCiv.

Subscribe to our mailing list

* indicates required